ARTICLE | Clinical News
Prolia denosumab regulatory update
September 20, 2010 7:00 AM UTC
The U.K.'s NICE issued a final appraisal determination (FAD) recommending use of Prolia denosumab from Amgen for the primary and secondary prevention of osteoporotic fragility fractures only in postme...